Trinity Biotech plc has entered into a series of financing agreements with funds managed by Perceptive Advisors to strengthen its capital structure and support its growth initiatives. The arrangements include $5 million in new term-loan funding and an extension of the company's credit agreement maturity to January 15, 2027. The agreements also introduce up to $60 million in elective equitization capacity under the term-loan, potentially reducing debt and interest costs, as well as equity settlement mechanisms for $5 million in milestone payments and $7.5 million in contingent obligations. These measures are aimed at increasing Trinity Biotech’s financial flexibility and supporting the development of its diabetes management solutions and diagnostic technologies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trinity Biotech plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9616576-en) on December 23, 2025, and is solely responsible for the information contained therein.